Nutritional, Metabolic, Endocrine
Conditions
Interventions
Standard care
Glucophage tablets
Sponsors
Lucy Ochola
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients currently on or are being initiated on high-dose prednisone-based chemotherapy (>30mg/day) with hematological cancers (ALL, NHL, CLL, HL and MM). 2.Patients with postprandial blood glucose readings indicating no hyperglycemia prior to enrollment in the study. 3.Patients aged 18 years and above. 4.Patient having adequate renal function prior to enrollment to the study with a serum creatinine levels of 30mL/min per 1.73m2. 5.Patients with adequate electrolyte balance particularly serum lactate levels <5 mmol/L. 6.Patients showing willingness to comply with the study protocol and have a signed informed consent. 7.Patients with normal hemoglobin reference values from full hemogram tests.
Exclusion criteria
Exclusion criteria: 1.Patients on prednisone treatment for any other indication other than hematological cancers, 2.Patients with pre-existing diagnosed diabetes mellitus, 3.Patients recently exposed or awaiting radiocontrast procedures, patients with recent exposure (less than 3 months) to metformin, 4.Patients with more than one cancer where the additional cancer is non-hematological, 5.Patients on medication that may contribute to hyperglycemia like thiazide diuretics, beta-blockers, protease inhibitors, statins, niacin, phenytoin, atypical anti-psychotics, oral contraceptives and L-asparaginase, 6.Pregnant patients, 7.Patients with significant electrolyte disturbances, 8.Patients with tissue hypoxia like cardiac or respiratory insufficiencies, 9.Patients consuming three or more alcoholic drinks per day, 10.Patients with concurrent severe illness and patients currently on any other antidiabetic therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is to compare the effectiveness of metformin in preventing prednisone-induced hyperglycemia among hematological cancer patients on high-dose prednisone chemotherapy at Kenyatta National Hospital | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the postprandial blood glucose levels achieved by single versus double daily metformin dosing among adult hematological cancer patients receiving high-dose prednisone.;To determine the incidence of pre-diabetes and diabetes among adult hematological cancer patients receiving prednisone-based regimens with no metformin prophylaxis of prednisone-induced hyperglycemia | — |
Countries
Kenya
Contacts
Public ContactZipporah A
Secretary of Pharmacy School
Outcome results
None listed